Can Tremfya turn radiographic evidence into a commercial advantage for Johnson & Johnson?
Find out how Johnson & Johnson’s Tremfya label expansion could reshape IL-23 competition in psoriatic arthritis care.
Pharma & Biotech
Pharma & Biotech
Why Bristol Myers Squibb’s Sotyktu approval could reshape the oral psoriatic arthritis race
A new EU approval is only the first hurdle. Sotyktu now faces Europe’s tougher test: payer access, sequencing, and real-world uptake.
Pharma & Biotech
Gazyva’s ALLEGORY data: what the SRI-4 and DORIS remission outcomes mean for lupus care
Genentech's obinutuzumab met all ALLEGORY phase III endpoints in SLE. What the remission and flare data mean for lupus treatment strategy.
Pharma & Biotech
Sobi bets $950m on Arthrosi to reshape chronic gout treatment with pozdeutinurad
Swedish Orphan Biovitrum AB (Sobi) has entered into a definitive agreement to acquire Arthrosi Therapeutics Inc. for $950 million upfront and up to $550 million in milestone payments. The deal brings the investigational gout drug pozdeutinurad (AR882) into Sobi’s pipeline, positioning the oral URAT1 inhibitor as a potential anchor asset in a late-stage inflammatory franchise.